alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<ARTICLE> 5
<CURRENCY> 
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          OCT-31-1996
<PERIOD-START>                             NOV-01-1995
<PERIOD-END>                               JAN-31-1996
<EXCHANGE-RATE>                                      1
<CASH>                                      17,889,242
<SECURITIES>                                         0
<RECEIVABLES>                                  683,427
<ALLOWANCES>                                    80,000
<INVENTORY>                                  6,999,454
<CURRENT-ASSETS>                            25,795,722
<PP&E>                                       8,477,571
<DEPRECIATION>                               5,269,559
<TOTAL-ASSETS>                              29,401,681
<CURRENT-LIABILITIES>                        6,079,770
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                      1,275
<COMMON>                                        70,433
<OTHER-SE>                                  20,007,555
<TOTAL-LIABILITY-AND-EQUITY>                29,401,681
<SALES>                                        707,033
<TOTAL-REVENUES>                             5,625,836
<CGS>                                          456,759
<TOTAL-COSTS>                                2,726,584
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              2,442,493
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          2,442,493
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 2,442,493
<EPS-PRIMARY>                                      .39
<EPS-DILUTED>                                      .39
        

</TABLE>
§ 803.1 What does this part cover? ( a ) This part establishes the requirements for medical device reporting for device user facilities, manufacturers, importers, and distributors. If you are a device user facility, you must report deaths and serious injuries that a device has or may have caused or contributed to, establish and maintain adverse event files, and submit summary annual reports. If you are a manufacturer or importer, you must report deaths and serious injuries that your device has or may have caused or contributed to, you must report certain device malfunctions, and you must establish and maintain adverse event files. If you are a manufacturer, you must also submit specified followup. These reports help us to protect the public health by helping to ensure that devices are not adulterated or misbranded and are safe and effective for their intended use. If you are a medical device distributor, you must maintain records (files) of incidents, but you are not required to report these incidents.
( b ) This part supplements and does not supersede other provisions of this chapter, including the provisions of part 820 of this chapter.
( c ) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Commerce

###### National Oceanic and Atmospheric Administration

# AGENCY:

National Oceanic and Atmospheric Administration (NOAA), Office of Ocean and Coastal Resource Management, National Ocean Service, Commerce.

# ACTION:

Notice of intent to evaluate—rescheduled site visit and public meeting.

# SUMMARY:

                        The NOAA Office of Ocean and Coastal Resource Management (OCRM) announces a rescheduled site visit and time for a public meeting previously included in an announcement of intent to evaluate the performance of the Rhode Island Coastal Management Program. Notice was previously given in the                         **Federal Register**                         on Monday, December 7, 2009, of the date of the site visit for the evaluation of the Rhode Island Coastal Management Program and the date, local time, and location of the public meeting. Notice is hereby given of the rescheduled date for the site visit and local time of the public meeting during the site visit.                    

# Date and Time:

The Rhode Island Coastal Management Program evaluation site visit will be held February 22-26, 2010. One public meeting will be held during the week. The public meeting will be held on Wednesday, February 24, 2010, at 6 p.m. in Conference Room A, Department of Administration, One Capitol Hill, Providence, Rhode Island.

# FOR FURTHER INFORMATION CONTACT:

Kate Barba, Chief, National Policy and Evaluation Division, Office of Ocean and Coastal Resource Management, NOS/NOAA, 1305 East-West Highway, 10th Floor, Silver Spring, Maryland 20910, (301) 563-1182.

      ( print page 8650)    
Dated: February 16, 2010.

Donna Wieting,

Acting Director, Office of Ocean and Coastal Resource Management, National Ocean Service, National Oceanic and Atmospheric Administration.

[FR Doc. 2010-3793 Filed 2-24-10; 8:45 am]

BILLING CODE 3510-08-P
#### § 1402.3 Information in the custody of ONDCP.

Information contained in ONDCP files and under the exclusive declassification jurisdiction of ONDCP will be reviewed by the Director of the Office of Planning, Budget, and Administration of ONDCP and/or the office of primary interest to determine whether, under the declassification provisions of section 3.1 of Executive Order 12356 (3 CFR, 1982 Comp., p. 166), the requested information may be declassified. If the information may not be released, in whole or in part, the requester shall be given a brief statement as to the reasons for denial, a notice of the right to appeal the determination to the Director of ONDCP, and a notice that such an appeal must be filed within 60 days in order to be considered.
§ 660.36 Samples and protocols. ( a ) The following shall be submitted to the Center for Biologics Evaluation and Research Sample Custodian (see mailing addresses in § 600.2(c) of this chapter), within 30 days after each routine establishment inspection by FDA. ( 1 ) From a lot of final product, samples from a cell panel intended for identification of unexpected antibodies. The sample shall be packaged as for distribution and shall have at least 14 days remaining in the dating period when shipped to the Center for Biologics Evaluation and Research.
( 2 ) A protocol which shall include the following: ( i ) Complete test records of at least two donors of the samples submitted, including original and confirmation phenotyping records.
( ii ) Bleeding records or receipt records which indicate collection date, volume, and HBsAg test results.
( iii ) Manufacturing records which document all steps involved in the preparation of the product.
( iv ) Test results which verify that the final product meets specifications.
( v ) Identity test results.
( b ) A copy of the antigenic constitution matrix specifying the antigens present or absent shall be submitted to the Director, Center for Biologics Evaluation and Research (see mailing addresses in § 600.2(c) of this chapter), at the time of initial distribution of each lot of Reagent Red Blood Cells for detection or identification of unexpected antibodies. Products designed exclusively to identify Anti-A, Anti-A1, and Anti-B, as well as products composed entirely of umbilical cord cells, are excluded from this requirement.
( c ) Except for umbilical cord samples, whenever a new donor is used, a sample of red blood cells from each new donor used in a cell panel intended for the identification of unexpected antibodies shall be submitted by the manufacturer to the Director, Center for Biologics Evaluation and Research (see mailing addresses in § 600.2(c) of this chapter). The sample should contain a minimum volume of 0.5 milliliter of red blood cells.
[52 FR 37450, Oct. 7, 1987, as amended at 55 FR 11013, 11015, Mar. 26, 1990; 67 FR 9587, Mar. 4, 2002; 70 FR 14985, Mar. 24, 2005; 80 FR 18093, Apr. 3, 2015]
[Federal Register Volume 75, Number 39 (Monday, March 1, 2010)]
[Notices]
[Page 9181]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4104]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

International Trade Administration


Secretarial China Clean Energy Business Development Mission; 
Application Deadline Extended

AGENCY: International Trade Administration, Department of Commerce.

ACTION: Notice.

-----------------------------------------------------------------------

Timeframe for Recruitment and Applications

    Mission recruitment will be conducted in an open and public manner, 
including publication in the Federal Register, posting on the Commerce 
Department trade mission calendar (http://www.ita.doc.gov/doctm/tmcal.html) and other Internet Web sites, press releases to general and 
trade media, direct mail, broadcast fax, notices by industry trade 
associations and other multiplier groups, and publicity at industry 
meetings, symposia, conferences, and trade shows. The Commerce 
Department's Office of Business Liaison and the International Trade 
Administration will explore and welcome outreach assistance from other 
interested organizations, including other U.S. Government agencies.
    Recruitment for this mission will begin immediately upon approval. 
Applications can be completed on-line at the Clean Energy Business 
Development Missions' Web site at http://www.trade.gov/CleanEnergyMission or can be obtained by contacting the U.S. Department 
of Commerce Office of Business Liaison (202-482-1360 or 
<a href="/cdn-cgi/l/email-protection#9ad9f6fffbf4dff4ffe8fde3d7f3e9e9f3f5f4dafef5f9b4fdf5ec"><span class="__cf_email__" data-cfemail="20634c45414e654e455247596d495353494f4e60444f430e474f56">[email protected]</span></a>). The application deadline has been extended 
to Friday, March 12, 2010. Completed applications should be submitted 
to the Office of Business Liaison. Applications received after Friday, 
March 12, 2010 will be considered only if space and scheduling 
constraints permit.

Contacts

    The Office of Business Liaison, 1401 Constitution Avenue, NW., Room 
5062, Washington, DC 20230, Tel: 202-482-1360, Fax: 202-482-4054, E-
mail: <a href="/cdn-cgi/l/email-protection#1d5e71787c735873786f7a6450746e6e7472735d79727e337a726b"><span class="__cf_email__" data-cfemail="d291beb7b3bc97bcb7a0b5ab9fbba1a1bbbdbc92b6bdb1fcb5bda4">[email protected]</span></a>.

Sean Timmins,
Global Trade Programs, Commercial Service Trade Missions Program.
[FR Doc. 2010-4104 Filed 2-26-10; 8:45 am]
BILLING CODE P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          FEB-29-2000
<PERIOD-START>                             MAR-01-1999
<PERIOD-END>                               NOV-30-1999
<CASH>                                           1,686
<SECURITIES>                                         0
<RECEIVABLES>                                    8,037
<ALLOWANCES>                                         0
<INVENTORY>                                    291,036
<CURRENT-ASSETS>                                     0
<PP&E>                                           8,596
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 335,305
<CURRENT-LIABILITIES>                                0
<BONDS>                                         97,800
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,500
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   335,305
<SALES>                                        192,787
<TOTAL-REVENUES>                               192,787
<CGS>                                          154,853
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                20,684
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              14,836
<INCOME-PRETAX>                                  3,378
<INCOME-TAX>                                       846
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                    200
<CHANGES>                                            0
<NET-INCOME>                                     2,732
<EPS-BASIC>                                        .20
<EPS-DILUTED>                                      .20


</TABLE>
§ 582.1005 Acetic acid. ( a ) *Product.* Acetic acid.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
# C_2016222EN.01004804.xml

| 20.6.2016 | EN | Official Journal of the European Union | C 222/48 |
| --- | --- | --- | --- |

20.6.2016

EN

Official Journal of the European Union

C 222/48

---

Order of the Civil Service Tribunal of 4 May 2016 — Leon-Gonzalez and Vander Velde v Commission

(Case F-47/14) (1)

(2016/C 222/73)

Language of the case: French

The President of the Second Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 212, 7/7/2014, p. 47.

---
IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 11-31027

DWAN TAPP

Plaintiff-Appellant

v.

WHIRLPOOL CORPORATION,

formerly known as Maytag Corporation,

Defendant-Appellee

Appeal from the United States District Court

for the Eastern District of Louisiana

USDC No. 2:08-CV-1134

Before JONES, Chief Judge, and WIENER and GRAVES, Circuit Judges.

PER CURIAM:*

There being no reversible error, the judgment of the district court is

AFFIRMED. See 5TH CIRCUIT LOC. RULE 47.6.

United States Court of Appeals

Fifth Circuit

F I L E D

June 15, 2012

Lyle W. Cayce

Clerk

Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not be *

published and is not precedent except under the limited circumstances set forth in 5TH CIR. R. 47.5.4.

Case: 11-31027 Document: 00511888155 Page: 1 Date Filed: 06/15/2012
NOT FINAL UNTIL TIME EXPIRES TO FILE REHEARING

MOTION AND, IF FILED, DETERMINED

IN THE DISTRICT COURT OF APPEAL

OF FLORIDA

SECOND DISTRICT

In the Interest of J.K. and A.P., children. )

___________________________________)

)

GUARDIAN AD LITEM PROGRAM and )

DEPARTMENT OF CHILDREN AND )

FAMILIES, )

)

Appellants, )

)

v. ) Case No. 2D18-1614 

) 2D18-1616 

) 

) CONSOLIDATED 

T.K. and S.P., )

)

Appellees. )

___________________________________)

Opinion filed August 24, 2018. 

Appeal from the Circuit Court for Collier 

County; Geoffrey H. Gentile, Judge.

Thomasina Moore, Statewide Director of 

Appeals, Tallahassee, and Laura J. Lee, 

Appellate Counsel, Sanford, for Appellant 

Guardian ad Litem Program.

Meredith K. Hall, Appellate Counsel, 

Children Legal Services, Bradenton, for 

Appellant Department of Children and 

Families. 

Ita M. Neymotin, Regional Counsel, 

Second District, and Joseph Thye 

Sexton, Assistant Regional Counsel, 

Office of Criminal Conflict and Civil
- 2 -

Regional Counsel, Bartow, for 

Appellee T.K.

Toni A. Butler of Alderuccio & Butler, LLC, 

Naples, for Appellee S.P. 

PER CURIAM.

Affirmed.

CASANUEVA, CRENSHAW, and SALARIO, JJ., Concur.
INDEPENDENT AUDITORS' CONSENT

                                                                    EXHIBIT 23.1

INDEPENDENT AUDITORS' CONSENT

We consent to the incorporation by reference in this Registration Statement of
4Kids Entertainment, Inc. on Form S-8 of our report dated March 25, 2002,
appearing in the Annual Report on Form 10-K of 4Kids Entertainment, Inc. for the
year ended December 31, 2001.

Deloitte & Touche LLP
New York, New York
November 27, 2002
# C_2014421EN.01002201.xml

| 24.11.2014 | EN | Official Journal of the European Union | C 421/22 |
| --- | --- | --- | --- |

24.11.2014

EN

Official Journal of the European Union

C 421/22

---

Request for a preliminary ruling from the Augstākā tiesa (Latvia) lodged on 19 September 2014 — Valsts ieņēmumu dienests v Artūrs Stretinskis

(Case C-430/14)

2014/C 421/32

Language of the case: Latvian

Referring court

Referring court

Augstākā tiesa

Parties to the main proceedings

Parties to the main proceedings

Applicant: Valsts ieņēmumu dienests

Applicant:

Defendant: Artūrs Stretinskis

Defendant:

Questions referred

Questions referred

| 1. | Must Article 143(1)(h) of Commission Regulation No 2454/93 (1) of 2 July 1993 laying down provisions for the implementation of Council Regulation (EEC) No 2913/92 (2) establishing the Community Customs Code be interpreted as referring not only to situations in which the parties to the transaction are exclusively natural persons, but also to situations in which there is a family or kinship relationship between a director of one of the parties (a legal person) and the other party to the transaction (a natural person) or a director of that party (in the case of a legal person)? |
| --- | --- |

1.

Must Article 143(1)(h) of Commission Regulation No 2454/93 (1) of 2 July 1993 laying down provisions for the implementation of Council Regulation (EEC) No 2913/92 (2) establishing the Community Customs Code be interpreted as referring not only to situations in which the parties to the transaction are exclusively natural persons, but also to situations in which there is a family or kinship relationship between a director of one of the parties (a legal person) and the other party to the transaction (a natural person) or a director of that party (in the case of a legal person)?

1

2

| 2. | If the answer is affirmative, must the judicial body hearing the matter carry out an in-depth examination of the circumstances of the case in relation to the actual influence of the natural person concerned over the legal person? |
| --- | --- |

2.

If the answer is affirmative, must the judicial body hearing the matter carry out an in-depth examination of the circumstances of the case in relation to the actual influence of the natural person concerned over the legal person?

---

(1)  OJ 1993 L 253, p. 1.

1

(2)  OJ 1992 L 302, p. 1.

2

---
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE GULFWEST
OIL  COMPANY'S  QUARTERLY  REPORT  FILED ON FORM  10-Q/A FOR THE  QUARTER  ENDED
SEPTEMBER  30,  1997 AND IS  QUALIFIED  IN ITS  ENTIRETY  BY  REFERENCE  TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<CIK>                         0000813779
<NAME>                        0
<MULTIPLIER>                  1                
<CURRENCY>                    0                
       
<S>                             <C>
<PERIOD-TYPE>                  9-MOS
<FISCAL-YEAR-END>              DEC-31-1996     
<PERIOD-START>                 JUL-1-1997    
<PERIOD-END>                   SEP-30-1997    
<EXCHANGE-RATE>                1               
<CASH>                         100,764         
<SECURITIES>                   0               
<RECEIVABLES>                  688,669         
<ALLOWANCES>                   0               
<INVENTORY>                    0               
<CURRENT-ASSETS>               970,312         
<PP&E>                         17,876,630      
<DEPRECIATION>                 2,136,293       
<TOTAL-ASSETS>                 16,706,815      
<CURRENT-LIABILITIES>          5,334,774       
<BONDS>                        0               
<PREFERRED-MANDATORY>          0               
<PREFERRED>                    54              
<COMMON>                       1,753           
<OTHER-SE>                     3,194,758       
<TOTAL-LIABILITY-AND-EQUITY>   16,706,815      
<SALES>                        3,132,514       
<TOTAL-REVENUES>               3,551,162       
<CGS>                          0               
<TOTAL-COSTS>                  3,478,989       
<OTHER-EXPENSES>               0               
<LOSS-PROVISION>               0               
<INTEREST-EXPENSE>             (777,951)       
<INCOME-PRETAX>                (703,882)       
<INCOME-TAX>                   0               
<INCOME-CONTINUING>            (703,882)       
<DISCONTINUED>                 0               
<EXTRAORDINARY>                0               
<CHANGES>                      0               
<NET-INCOME>                   (703,882)       
<EPS-PRIMARY>                  (.53)           
<EPS-DILUTED>                  (.53)           
        

</TABLE>
§ 516.143 Written report. The written report required in § 516.145(b)(3) shall: ( a ) Be written in English by a qualified expert panel meeting the requirements of § 516.141;
( b ) Describe the panel's evaluation of all available target animal safety and effectiveness information relevant to the proposed use of the new animal drug, including anecdotal information;
( c ) For all information considered, including anecdotal information, include either a citation to published literature or a summary of the information;
( d ) State the panel's opinion regarding whether the benefits of using the new animal drug for the proposed use in a minor species outweigh its risks to the target animal, taking into account the harm being caused by the absence of an approved or conditionally-approved new animal drug for the minor species in question;
( e ) Be signed, or otherwise approved in writing, by all panel members, in accordance with § 516.141; and
( f ) If the panel unanimously concludes that the benefits of using the new animal drug for the proposed use in a minor species outweigh its risks to the target animal, taking into account the harm being caused by the absence of an approved or conditionally-approved new animal drug for the minor species in question, the written report shall: ( 1 ) Provide draft labeling that includes all conditions of use and limitations of use of the new animal drug deemed necessary by the panel to assure that the benefits of use of the new animal drug outweigh the risks, or provide narrative information from which such labeling can be written by the requestor; and
( 2 ) Include a recommendation regarding whether the new animal drug should be limited to use under the professional supervision of a licensed veterinarian.